Cited by 119Gut microbiota and healthLiver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

The DOI matches its Crossref record.

Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae

Open access

Yuan, Jing, Chen, Chen, Cui, Jinghua, Lu, Jing, Yan, Chao, Wei, Xiao, Zhao, Xiangna, Li, NanNan, Li, Shaoli, Xue, Guanhua, Cheng, Weiwei, Li, Boxing, Li, Huan, Lin, Weishi, Tian, Changyu, Zhao, Jiangtao, Han, Juqiang, An, Daizhi, Zhang, Qiong, Wei, Hong, Zheng, Minghua, Ma, Xuejun, Li, Wei, Chen, Xiao, Zhang, Zheng, Zeng, Hui, Ying, Sun, Wu, JianXin, Yang, Ruifu, Liu, Di·2019·Cell Metabolism

DOI 10.1016/j.cmet.2019.11.006

Open this paper in CoChat — free account Open PDF

Integrity signals

Registry

Crossref · 10.1016/j.cmet.2019.11.006

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Phage therapy: From biological mechanisms to future directions
Strathdee, S. A., Hatfull, G. F., Mutalik, V. K., & Schooley, R. T. (2023) · Cell · doi:10.1016/j.cell.2022.11.017 · Cited by 817
What's in a name? Renaming ‘NAFLD’ to ‘MAFLD’
Fouad, Y. M., Waked, I. A., Bollipo, S. J., Gomaa, A., Ajlouni, Y., & Attia, D. I. (2020) · Liver International · doi:10.1111/liv.14478 · Cited by 297
Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease
Romeo, S., Sanyal, A. J., & Valenti, L. V. C. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.12.002 · Cited by 206
Novel therapeutic targets for cholestatic and fatty liver disease
Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204
Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease
Sharpton, S. R., Schnabl, B., Knight, R., & Loomba, R. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.11.010 · Cited by 194
Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review
Rinaldi, L., Pafundi, P. C., Galiero, R., Caturano, A., Morone, M. V., Silvestri, C., Giordano, M., Salvatore, T., & Sasso, F. C. (2021) · Antioxidants · doi:10.3390/antiox10020270 · Cited by 180
Bacteriophage targeting microbiota alleviates non-alcoholic fatty liver disease induced by high alcohol-producing Klebsiella pneumoniae
Gan, L., Feng, Y., Du, B., Fu, H., Tian, Z., Xue, G., Yan, C., Cui, X., Zhang, R., Cui, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39028-w · Cited by 162
“Speci ﬁ c-pathogen-free (SPF) male C57BL/6J mice (6-7 weeks old, Charles River Corp., Beijing, China) were used for establishing murine models as previously described 7 .”
InfluentialSelf-citation
Evolving Role for Pharmacotherapy in NAFLD/NASH
Attia, S. L., Softic, S., & Mouzaki, M. (2020) · Clinical and Translational Science · doi:10.1111/cts.12839 · Cited by 131
“This review summarizes emerging pharmacotherapies for the treatment of adult and pediatric NAFLD.”
BackgroundInfluential
Gut-microbiome-expressed 3β-hydroxysteroid dehydrogenase degrades estradiol and is linked to depression in premenopausal females
Li, D., Sun, T., Tong, Y., Le, J., Yao, Q., Tao, J., Liu, H., Jiao, W.-E., Mei, Y., Chen, J., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.02.017 · Cited by 112
Bacteriophage therapy against pathological Klebsiella pneumoniae ameliorates the course of primary sclerosing cholangitis
Ichikawa, M., Nakamoto, N., Kredo‐Russo, S., Weinstock, E., Weiner, I. N., Khabra, E., Ben-Ishay, N., Inbar, D., Kowalsman, N., Mordoch, R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39029-9 · Cited by 115
Acetate reprograms gut microbiota during alcohol consumption
Martino, C., Zaramela, L. S., Gao, B., Embree, M., Tarasova, J., Parker, S. J., Wang, Y., Chu, H., Chen, P., Lee, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31973-2 · Cited by 110
Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?
Ratziu, V., & Friedman, S. L. (2023) · Gastroenterology · doi:10.1053/j.gastro.2020.05.046 · Cited by 88
Characterization of the gut‐liver‐muscle axis in cirrhotic patients with sarcopenia
Ponziani, F. R., Picca, A., Marzetti, E., Calvani, R., Conta, G., CHIERICO, F. D., Capuani, G., Faccia, M., Fianchi, F., Funaro, B., et al. (2021) · Liver International · doi:10.1111/liv.14876 · Cited by 93
Recent advances of sterile inflammation and inter-organ cross-talk in alcoholic liver disease
Shim, Y., & Jeong, W. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0438-5 · Cited by 81
Intestinal virome and therapeutic potential of bacteriophages in liver disease
Hsu, C. L., Duan, Y., Fouts, D. E., & Schnabl, B. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.08.003 · Cited by 78
New Insights into AMPK, as a Potential Therapeutic Target in Metabolic Dysfunction-Associated Steatotic Liver Disease and Hepatic Fibrosis
An, H., Jang, Y., Choi, J.-I., Hur, J., Kim, S., & Kwon, Y. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.188 · Cited by 75
Comparison of Metagenomics and Metatranscriptomics Tools: A Guide to Making the Right Choice
Terron-Camero, L. C., Gordillo-González, F., Salas‐Espejo, E., & Andrés‐León, E. (2022) · Genes · doi:10.3390/genes13122280 · Cited by 74
Impact of drinking alcohol on gut microbiota: recent perspectives on ethanol and alcoholic beverage
Lee, E., & Lee, J. (2020) · Current Opinion in Food Science · doi:10.1016/j.cofs.2020.10.001 · Cited by 61
The role of intestinal stem cell within gut homeostasis: Focusing on its interplay with gut microbiota and the regulating pathways
Luo, H., Li, M., Wang, F., Yang, Y., Wang, Q. L., Zhao, Y., Du, F., Chen, Y., Shen, J., Zhao, Q., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.72600 · Cited by 58
Self-citation
The Potential Gut Microbiota-Mediated Treatment Options for Liver Cancer
Zhang, C., Yang, M. J., & Ericsson, A. C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.524205 · Cited by 51
“For instance, high-alcohol-producing bacterium Klebsiella pneumoniae is implicated in the pathogenesis of NAFLD in human patients, evidenced by oral gavage of a clinically isolated strain causing NAFLD in mice (29).”
Background
Isolation and genomic characterization of five novel strains of Erysipelotrichaceae from commercial pigs
Wu, J., Liu, M., Zhou, M., Wu, L., Yang, H., Huang, L., & Chen, C. (2021) · BMC Microbiology · doi:10.1186/s12866-021-02193-3 · Cited by 50
Self-citation
The role of microbiota in nonalcoholic fatty liver disease
Ciaula, A. D., Bonfrate, L., & Portincasa, P. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13768 · Cited by 44
A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression
Iruzubieta, P., Medina, J. M., Fernández-López, R., Crespo, J., & de la Cruz, F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051369 · Cited by 44
“This was proven in a recent study, where the introduction of strains of Klebsiella pneumoniae with high alcohol production induced NAFLD in mice [56].”
Result
Gut microbiome signatures distinguish type 2 diabetes mellitus from non-alcoholic fatty liver disease
Si, J., Lee, G., You, H. J., Joo, S. K., Lee, D. H., Ku, B. J., Park, S., Kim, W. K., & Ko, G. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.10.032 · Cited by 43
Metabolic and alcohol-associated liver disease (MetALD): a representation of duality
Leal-Lassalle, H., Estévez‐Vázquez, O., Cubero, F. J., & Nevzorova, Y. A. (2025) · npj gut and liver. · doi:10.1038/s44355-024-00014-8 · Cited by 50
“Bacterial species belonging to the phylum Proteobacteria, lactic acid bacteria and Klebsiella pneumoniae 121 have been associated with fasting alcohol levels in MASLD.”
Advances in the acting mechanism and treatment of gut microbiota in metabolic dysfunction-associated steatotic liver disease
Wu, H., Chen, J., Guo, S., Deng, J., Zhou, Z., Zhang, X., Qi, T., Yu, F., & Yang, Q. L. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2500099 · Cited by 42
“75 Some researchers have identified other ethanol-producing microbiota in the gut, such as Limosilactobacillus fer-mentum, Enterocloster bolteae, Mediterraneibacter gnavus, Streptococcus mutans, Pichia kudriavzevii, Candida albicans and Candida glabrata Yeasts.”
Human Gut Microbiome and Liver Diseases: From Correlation to Causation
Li, R., Mao, Z., Ye, X., & Zuo, T. (2021) · Microorganisms · doi:10.3390/microorganisms9051017 · Cited by 40
Probiotics, prebiotics, and synbiotics in nonalcoholic fatty liver disease and alcohol-associated liver disease
Kaufmann, B. K., Seyfried, N., Hartmann, D., & Hartmann, P. (2023) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00017.2023 · Cited by 40
The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease
Francisco Barrera, M., Uribe, J., Olvares, N., Huerta, P., Cabrera, D., & Romero‐Gómez, M. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101501 · Cited by 38
Interplay of Oxidative Stress, Gut Microbiota, and Nicotine in Metabolic-Associated Steatotic Liver Disease (MASLD)
Mignini, I., Galasso, L., Piccirilli, G., Calvez, V., Termite, F., Esposto, G., Borriello, R., Miele, L., Ainora, M. E., Gasbarrini, A., et al. (2024) · Antioxidants · doi:10.3390/antiox13121532 · Cited by 39
“The rise in Bacteroidetes leads to increased methanol production, which can accumulate and cause oxidative damage in the gut and liver [82,83], a process that may be further worsened by alcohol-producing strains of K. pneumoniae [84,85].”
Understanding MASLD — from molecular pathogenesis to cardiovascular risk: A concise review for the clinical cardiologist
Ratti, C., Malaguti, M., D’Aniello, E., Bellasi, A., & Sanna, G. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120495 · Cited by 42
Seven facts and five initiatives for gut microbiome research
Li, D., Gao, C., Zhang, F., Yang, R., Lan, C., Ma, Y., & Wang, J. (2020) · Protein & Cell · doi:10.1007/s13238-020-00697-8 · Cited by 36
Self-citation
Targeting the Gut Microbiome to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: Ready for Prime Time?
Lanthier, N., & Delzenne, N. M. (2022) · Cells · doi:10.3390/cells11172718 · Cited by 35
Gut microbiota in MAFLD: therapeutic and diagnostic implications
Alghamdi, W., Mosli, M. H., & Alqahtani, S. A. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188241242937 · Cited by 33
“29,111,112 BAs and SCFAs.”
Gut microbiota–NLRP3 inflammasome crosstalk in metabolic dysfunction-associated steatotic liver disease
Yu, T., Luo, L., Xue, J., Tang, W., Wu, X., & Fan, Y. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102458 · Cited by 41
Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets
Santos‐Laso, Á., Gutiérrez‐Larrañaga, M., Alonso‐Peña, M., Medina, J. M., Iruzubieta, P., Arias, M., López‐Hoyos, M., & Crespo, J. (2021) · Biomedicines · doi:10.3390/biomedicines10010046 · Cited by 34
Multi-Omics Reveals Inhibitory Effect of Baicalein on Non-Alcoholic Fatty Liver Disease in Mice
Li, P., Hu, J., Zhao, H., Feng, J., & Chai, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.925349 · Cited by 31
“Increasing evidence shows that disturbances in the gut microbiota may result in liver diseases including NAFLD (Tokuhara, 2021), since nutrients and microbiota-related components transfer from the intestines to the liver directly through the portal tract (Chen et al., 2019; Hong et al., 2019; Suk and Kim, 2019; Yuan e…”
Background
Insoluble/soluble fraction ratio determines effects of dietary fiber on gut microbiota and serum metabolites in healthy mice
Zhang, Y. L., Hu, J., Zhong, Y., Liu, S., Liu, L., Mu, X., Chen, C., Yang, S., Li, G., Zhang, D., et al. (2023) · Food & Function · doi:10.1039/d3fo04068b · Cited by 28
Self-citation
Harnessing stepping-stone hosts to engineer, select, and reboot synthetic bacteriophages in one pot
Li, C., Deng, Z., Tao, H., Song, W., Xing, B., Liu, W., Kong, L., Yuan, S., Ma, Y., Wu, Y., et al. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100217 · Cited by 26
“In these cases, SHAPE might be an interesting option for building synthetic phages to treat chronic gut microbiome-related diseases (Dong et al., 2020; Duan et al., 2019; Kabwe et al., 2021; Yuan et al., 2019; Zheng et al., 2019).”
Background
Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis
Yao, N., Yang, Y., Li, X., Wang, Y., Guo, R., Wang, X., Li, J., Xie, Z., Li, B., & Cui, W. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.906511 · Cited by 29
“Clostridium (87–89)] can also accelerate the development of MAFLD (88).”
BackgroundSelf-citation
The Gut Microbiota and Diabetes: Research, Translation, and Clinical Applications—2023 Diabetes , Diabetes Care , and Diabetologia Expert Forum
Byndloss, M. X., Devkota, S., Duca, F. A., Niess, J. H., Nieuwdorp, M., Orho‐Melander, M., Sanz, Y., Tremaroli, V., & Zhao, L. (2024) · Diabetes Care · doi:10.2337/dci24-0052 · Cited by 32
New perspective on fecal microbiota transplantation in liver diseases
Suk, K. T., & Koh, H. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15729 · Cited by 28
Two years on, a perspective on MAFLD
Eslam, M., & George, J. (2023) · eGastroenterology · doi:10.1136/egastro-2023-100019 · Cited by 26
Immunological dynamics in MASH: from landscape analysis to therapeutic intervention
Rabiu, L., Zhang, P., Afolabi, L. O., Saliu, M. A., Dabai, S. M., Suleiman, R. B., Gidado, K. I., Ige, M. A., Ibrahim, A., Zhang, G., et al. (2024) · Journal of Gastroenterology · doi:10.1007/s00535-024-02157-0 · Cited by 24
“For instance, Kleb‑ siella pneumoniae , an alcohol-producing bacterium, and Porphyromonas gingivalis are associated with increased fibrosis, with the latter directly promoting HSC activation, linking specific microbial strains to immune-mediated fibrogenesis [117–119].”
Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD
Gupta, M., Krishan, P., Kaur, A., Arora, S., Trehanpati, N., Singh, T. G., & Bedi, O. (2021) · Inflammation Research · doi:10.1007/s00011-021-01480-z · Cited by 21
“Liver–gut” axis: A target of traditional Chinese medicine for the treatment of non-alcoholic fatty liver disease
Guo, K., Xu, S., & Zeng, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1050709 · Cited by 20
The paradigm shift from NAFLD to MAFLD : A global primary care viewpoint
Farahat, T. M., Ungan, M., Vilaseca, J., Ponzo, J., Gupta, P. P., Schreiner, A. D., Sharief, W., Casler, K., Abdelkader, T., Abenavoli, L., et al. (2022) · Liver International · doi:10.1111/liv.15188 · Cited by 21
Gut mycobiome in metabolic diseases: Mechanisms and clinical implication
Zhou, X., Zhang, X., & Yu, J. Q. (2023) · Biomedical Journal · doi:10.1016/j.bj.2023.100625 · Cited by 22
“Bacteria such as Klebsiella pneumoniae [51], Escherichia [52] and Citrobacter [53] were reported to produced endogenous ethanol in NASH.”
Background
Betaine regulates the gut-liver axis: a therapeutic approach for chronic liver diseases
Perumal, S. K., Arumugam, M. K., Osna, N. A., Rasineni, K., & Kharbanda, K. K. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1478542 · Cited by 22
“…through various mechanisms, including disruption of liver choline metabolism (necessary for VLDL synthesis and liver lipid export) (150), alterations in bile acid synthesis (151, 152), ethanol production (153), and increased lipopolysaccharides (LPS), which results in liver inflammation (154–156).”
Fecal Metagenomics and Metabolomics Identifying Microbial Signatures in Non-Alcoholic Fatty Liver Disease
Pekkala, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054855 · Cited by 22
“Previously, it has been shown, for instance, that high-alcohol-producing strains of Klebsiella pneumoniae exist in humans with NAFLD [40].”
Background
Oral Probiotic Expressing Human Ethanol Dehydrogenase Attenuates Damage Caused by Acute Alcohol Consumption in Mice
Jiang, X., Yan, C., Zhang, H., Chen, L., Jiang, R. J., Zheng, K., Jin, W., Ma, H., Liu, X., & Dong, M. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04294-22 · Cited by 18
“Endogenous ethanol produced by intestinal bacteria impaired mitochondrial function in NAFLD (51).”
BackgroundSelf-citation
The role of the gut microbiome in graft fibrosis after pediatric liver transplantation
Qin, T., Fu, J., & Verkade, H. J. (2020) · Human Genetics · doi:10.1007/s00439-020-02221-8 · Cited by 18
N-(3-oxododecanoyl)-homoserine lactone disrupts intestinal barrier and induces systemic inflammation through perturbing gut microbiome in mice
Cheng, W., Wang, Z., Xiong, Y., Wu, Z., Tan, X., Yang, Y., Zhang, H., Zhu, X., Wei, H., & Tao, S. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.146347 · Cited by 16
Self-citation
Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets
Gruzdev, S., Podoprigora, I. V., & Gizinger, O. A. (2024) · Archives of Microbiology · doi:10.1007/s00203-023-03752-0 · Cited by 17
“One of the articles has demonstrated that Klebsiella pneumoniae A7 produces large amounts of endogenous alcohol that was linked to NAFLD progression in humans (Yuan et al. 2019).”
Inflammatory liver diseases and susceptibility to sepsis
Lü, H. (2024) · Clinical Science · doi:10.1042/cs20230522 · Cited by 18
Modulation effect of sulfated polysaccharide from Sargassum fusiforme on gut microbiota and their metabolites in vitro fermentation
Jiang, L., Chen, S., Ai, C., Wen, C., & Song, S. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1400063 · Cited by 17
The role of integration host factor in biofilm and virulence of high-alcohol-producing Klebsiella pneumoniae
Fan, Z., Fu, T., Li, Z., Du, B., Cui, X., Zhang, R., Feng, Y., Zhao, H., Xue, G., Cui, J., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.01170-23 · Cited by 15
“Our previous study found that HiAlc Kpn is associated with nearly 60% of individu als with NAFLD in a Chinese cohort (2).”
BackgroundInfluentialSelf-citation
Utilization of Food-Derived β-Glucans to Prevent and Treat Non-Alcoholic Fatty Liver Disease (NAFLD)
Kei, N., Wong, V. W., Lauw, S., You, L., & Cheung, P. C. K. (2023) · Foods · doi:10.3390/foods12173279 · Cited by 14
Extraintestinal manifestations of inflammatory bowel disease, nitroxidative stress and dysbiosis: What is the link between them?
Martins, A. S. D. P., Campos, S. B. G., Goulart, M. O. F., Fabiana, & Moura, F. A. (2021) · Biocell · doi:10.32604/biocell.2021.014332 · Cited by 13
Combined Methylation and Transcriptome Analysis of Liver Injury of Nonalcoholic Fatty Liver Disease Induced by High Alcohol-Producing Klebsiella pneumoniae
Zhang, R., Xu, Z., Xue, G., Feng, J., Du, B., Gan, L., Fan, Z., Fu, T., Feng, Y., Zhao, H., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.05323-22 · Cited by 12
“induced liver injury, which is consistent with the findings in a previous study (5).”
BackgroundMethodResultInfluentialSelf-citation
Interventions for non-alcoholic liver disease: a gut microbial metabolites perspective
Guo, J., Shi, C., Zhang, Q., Deng, W., Zhang, L., Chen, Q., Zhang, D., & Gong, Z. (2022) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848221138676 · Cited by 14
Self-citation
Nonalcoholic Fatty Liver Disease and the Intestinal Microbiome: An Inseparable Link
Effenberger, M., Grander, C., Grabherr, F., & Tilg, H. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00069 · Cited by 14
Novel approaches to liver disease diagnosis and modeling
de Oliveira, A. G., & Fiorotto, R. (2020) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh-20-109 · Cited by 10
An Update on the Role of the Microbiome in Non-alcoholic Fatty Liver Disease Pathogenesis, Diagnosis, and Treatment
Mouzaki, M., & Loomba, R. S. (2020) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-020-00290-2 · Cited by 8
Gut Microbiome and Cancer: From Cancer Development to Therapeutics with a Special Focus on Hepatocellular Carcinoma
Acharya, S., & Thirunavukkarasu, C. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2902067 · Cited by 10
Klebsiella pneumoniae-derived extracellular vesicles impair endothelial function by inhibiting SIRT1
Li, X., Cui, J., Ding, Z., Tian, Z., Kong, Y., Li, L., Liu, Y., Zhao, W., Chen, X., Guo, H., et al. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-024-02002-0 · Cited by 11
“K.pn strain with high alcohol-producing activity was confirmed to contribute to nonalcoholic fatty liver disease [10].”
InfluentialSelf-citation
Antibiotic Disruption of the Gut Microbiota Enhances the Murine Hepatic Dysfunction Associated With a High-Salt Diet
Zhang, Z., Li, M., Cui, B., & Chen, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.829686 · Cited by 9
Self-citation
Intestinal Microbiome in Dogs with Chronic Hepatobiliary Disease: Can We Talk about the Gut–Liver Axis?
Habermaass, V., Olivero, D., Gori, E., Mariti, C., Longhi, E., & Marchetti, V. (2023) · Animals · doi:10.3390/ani13203174 · Cited by 10
Gut microbiome influences exercise response
Greenhill, C. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0309-0 · Cited by 8
Fecal microbiota transplantation in a long-standing auto-brewery syndrome with complex symptomatology
Casañas, M., Barbero-Herranz, R., González, D. A., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.12.005 · Cited by 7
Hepatocellular Cancer and Gut Microbiome: Time to Untie Gordian’s Knot
Aygün, C., & Tozun, N. A. (2021) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-021-00736-5 · Cited by 7
“HCC Increased: Bacteroides, Bacteroidales, Ruminococcaceae, Enterococcus and Enterococceaea, Phascolarctobacterium, Oscillospira, Escherichia coli, Helicobacter pylori Decreased: Bifidobacterium, Bifidobacteriaceae, Bifidobacteriales, Bifidobacterium adolescentis, Blautia [4, 29]”
Result
Inulin alleviates HFD-induced NAFLD by hepatic macrophage polarization and lipid metabolism via gut-liver axis
Song, W., Hu, J., Zhu, L., Chen, B., Li, L., Cui, X., Zhang, T., Miao, Y., Su, K., Liu, C., et al. (2024) · Food Science and Human Wellness · doi:10.26599/fshw.2024.9250040 · Cited by 9
The Role of Gut Microbiota in Duodenal-Jejunal Bypass Surgery-Induced Improvement of Hepatic Steatosis in HFD-Fed Rats
Gao, Y., Zhang, J., Xiao, X., Ren, Y., Yan, X., Yue, J., Wang, T., Wu, Z., Lv, Y., & Wu, R. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.640448 · Cited by 7
Reduction of Bacteroides fragilis in Gut Microbiome of Chronic Hepatitis B Patients Promotes Liver Injury
You, Q., Wang, K., Zhao, Z., Zhou, H., Lan, Z., Liang, H., Deng, R., Li, W., Shen, S., Wang, R., et al. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70395 · Cited by 5
Self-citation
Factors in an Auto-Brewery Syndrome group compared to an American Gut Project group: a case-control study
Cordell, B., Kanodia, A. K., & Miller, G. K. (2021) · F1000Research · doi:10.12688/f1000research.52743.1 · Cited by 5
Torreya grandis polysaccharide alleviates acute lung injury via the lung–gut axis: Gut microbiota and immune regulation mechanisms
Hu, Y., Huang, Y., Wang, M., et al. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.153514 · Cited by 4
Self-citation
Mouse diet and vendor impact microbiome perturbation and recovery from early-life pulses of amoxicillin
Curtis-Joseph, N., Peterson, R., Brown, C. E., Beekman, C. N., & Belenky, P. A. (2024) · Frontiers in Microbiomes · doi:10.3389/frmbi.2024.1432202 · Cited by 6
“Understanding why these species bloom is important, as each species has multiple associated morbidities ranging from infection to auto-brewery syndrome (Yuan et al., 2019).”
Frequentmers - a novel way to look at metagenomic next generation sequencing data and an application in detecting liver cirrhosis
Mouratidis, I., Chantzi, N., Khan, U., Konnaris, M. A., Chan, C. S. Y., Mareboina, M., Moeckel, C., & Georgakopoulos-Soares, I. (2023) · BMC Genomics · doi:10.1186/s12864-023-09861-w · Cited by 3
“…show that the majority of high importance fre-quentmers originate from microorganisms known to be associated with liver cirrhosis, such as Prevotella copri , Faecalibacterium prausnitzii and Klebsiella pneumoniae , multiple of which have been previously associated with liver cirrhosis [24, 27, 28].”
Background
Reciprocal oscillation and host-microbial communication in liver metabolic control
Sun, J., & DeBosch, B. J. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2545413 · Cited by 3
Gold digging: Searching for gut microbiota that enhances antitumor immunity
Hou, F., Pan, Z., Yang, R., Zhi, F., & Bi, Y. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30272 · Cited by 2
Self-citation
Drivers of islet inflammation
Starling, S. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0159-9 · Cited by 3
AR-CDT NET: a deep deformable convolutional network for gut microbiome-based disease classification
Li, J., Sun, Z., Chai, S., Li, H.-J., Wang, Y., & Tian, J. (2025) · BMC Bioinformatics · doi:10.1186/s12859-025-06357-0 · Cited by 2
“This aligns with reports of endogenous alcohol production by gut bacteria, which can directly damage the liver and drive NAFLD progression [32].”
Self-citation
In vitro models of the gut-liver axis: what we’ve learned and what remains to be built
Sung, J. H., & Kim, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1858289 · Cited by 2
“However, speci ﬁ c microbial species, not their metabolites, can causally contribute to liver disease, as demonstrated by endotoxin-producing Enterobacter cloacae or high-alcohol-producing Klebsiella pneumoniae (67, 68).”
Microbiota and Liver Cancer
Wu, C., & Tseng, C. (2023) · Springer eBooks · doi:10.1007/978-981-19-4492-5_5 · Cited by 2
Multi-omics reveals the associations among the fecal metabolome, intestinal bacteria, and serum indicators in patients with hepatocellular carcinoma
Feng, J., Wang, J., Hu, J.-R., Li, P., Lv, P., He, H., Cheng, X.-W., Cao, Z., Han, J.-J., Wang, Q., et al. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i15.104996 · Cited by 1
Self-citation
Metabolic dysfunction-associated steatotic liver disease and the gut microbiome: a narrative review of pathophysiology, diagnostic value, and therapeutic approaches
Eun, J. W., Cheong, J. Y., & Kim, S. S. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.26.0074 · Cited by 1
Non-alcoholic Fatty Liver Disease - New Insight and Glance Into Disease Pathogenesis
Kang, S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100998 · Cited by 1
Revised Nomenclature for Fatty Liver Disease: Cutting through the Confusion
Alswat, K., Hashim, A. H., Alboraie, M. A. A., & Fouad, Y. M. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00049 · Cited by 1
Glutathione Ameliorates Mouse Steatohepatitis
Cai, Q. (2020) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2020.29.004851
Molecular Phenomics of Gut Ecosystem in COVID-19 PatientsPreprint
Yan, Z., He, F., He, H., Li, D., Pang, P., Fang, Z., Jiang, G., Huang, S., Li, K., Gu, Z., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-208797/v1
Self-citation
Metagenomics from bench to bedside and from bedside to bench
Jia, H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91369-0.00006-6 · Cited by 1
Strain-level analysis of microbial community and detection of mutually exclusive relationships uncover complexity of inflammatory bowel diseasePreprint
Shin, S., & Kim, J. F. (2020) · doi:10.21203/rs.2.24332/v1
Klebsiella pneumoniae aggravates lung injury through ethanol productionPreprint
Cui, J., Xu, Z., Yu, Z., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2082937/v1
Self-citation
Mechanisms of nonalcoholic fatty liver disease induced by antibiotic resistance and evaluation of bacteriophag-efficacyPreprint
Jin, X., Wu, J., Wang, C., Tang, B., Yang, H., & Liu, Y. (2023) · doi:10.22541/au.167587024.47659435/v1
Self-citation
Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targetsPreprint
Gruzdev, S., Viktorovna, P. I., & Anatolievna, G. O. (2023) · doi:10.22541/au.169332662.25916191/v1
Additional file 8 of Isolation and genomic characterization of five novel strains of Erysipelotrichaceae from commercial pigs
Wu, J., Liu, M., Zhou, M., Wu, L., Yang, H., Huang, L., & Chen, C. (2021) · Figshare · doi:10.6084/m9.figshare.14471681
Self-citation
Pathogenesis of NAFLD/NASH
Beier, J. I., Medici, V., Spencer, S. P., Fan, W., & Torok, N. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00006-6
Predicting the Imbalanced Impact of Drugs on Microbial Abundance Using Multi-View Learning and Data Augmentation
Zhu, B., Yu, H., Du, B.-X., Yu, H., & Shi, J. (2025) · Big Data Mining and Analytics · doi:10.26599/bdma.2024.9020094
Complete Genome and Characterization Analysis of a Bifidobacterium animalis Strain Isolated from Wild Pigs (Sus scrofa ussuricus)
Di, T., Zhang, H., Zhang, C., Tian, L., Chang, M., Han, W., Qiao, R., Li, M., Zhang, S., & Yang, G. (2025) · Microorganisms · doi:10.3390/microorganisms13071666
Phenotypes of non-alcoholic fatty liver disease in people with normal and increased body mass: issues of epidemiology and etiology, clinical and pathogenetic features and diagnostic approaches. Literature review
Shevlyukova, T. P., Bulatova, I. A., Vladimirskiy, V. E., Смирнова, E. N., Trofimova, E. S., & Yusupova, A. A. (2025) · Perm Medical Journal · doi:10.17816/pmj42420-40

Authors: Yuan, J., Chen, C., Cui, J., Lu, J., Yan, C., Wei, X., Zhao, X., Li, N., Li, S., Xue, G., Cheng, W., Li, B., Li, H., Lin, W., Tian, C., Zhao, J., Han, J., An, D., Zhang, Q., Wei, H., Zheng, M., Ma, X., Li, W., Chen, X., Zhang, Z., Zeng, H., Ying, S., Wu, J., Yang, R., & Liu, D.
Corresponding author: Yuan, Jing
Yang, Ruifu
Liu, Di
ORCID: Yuan, Jing
Cui, Jinghua
Lu, Jing
Yan, Chao
Zhao, Xiangna
Li, NanNan
Li, Shaoli
Cheng, Weiwei
Li, Boxing
Li, Huan
Lin, Weishi
Zhao, Jiangtao
Zhang, Qiong
Li, Wei
Zhang, Zheng
Zeng, Hui
Yang, Ruifu
Liu, Di
Venue: Cell Metabolism
Publisher: Elsevier BV
Published: 2019-12
Volume: 30
Issue: 6
Pages: 1172
ISSN: 1550-4131 (ISSN-L)
DOI: 10.1016/j.cmet.2019.11.006
OpenAlex: W4238732480
Cited by: 118
References: 0
Citations by year: 2026: 6 · 2025: 12 · 2024: 16 · 2023: 19 · 2022: 15 · 2021: 31 · 2020: 17 · 2019: 2
FWCI: 5.46
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 368 d)
Locations: Cell Metabolism (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords: non-alcoholic fatty liver disease, Klebsiella pneumoniae, gut microbiota, blood alcohol concentration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks